OUR FOCAL POINTS:
Creatine Transporter Deficiency
is an x-linked inborn error of creatine metabolism that results in an absence of creatine in the brain. This causes severe global developmental delay, mental retardation, Autistic behavior, and expressive speech deficits.LEARN MORE
Lumos Pharma Receives Wellcome Trust ..
Lumos Pharma Receives Wellcome Trust Award for Advancing Potential Treatment of Creatine Transporter Deficiency (CTD) Lumos Pharma, Inc. (Austin Texas) announced today that it has received an award of up to $5.5 million from the Translation Fund of the Wellcome Trust. CEO of Lumos Pharma, Richard Hawkins, stated “We are very pleased Wellcome Trust has […]READ MORE
Lumos Pharma Announces Series A Finan..
Financing provides for the development of Lumos Pharma’s lead compound, a novel treatment for Creatine Transporter Deficiency AUSTIN, Texas, Feb 4, 2014 – Lumos Pharma, an early stage biopharmaceutical development company, announced today that it has raised $14 million in Series A financing. The round was co-led by Santé Ventures and New Enterprise Associates (NEA). […]READ MORE
National Institutes of Health..
Researchers will begin drug development projects for rare and neglected diseases that include potential treatments for a musculoskeletal disorder, a cognitive dysfunction disorder, a virus that affects the central nervous system of newborns, a parasitic worm infection, a form of muscular dystrophy and a rare lung disease. The six new projects are part of the […]READ MORE